The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.36
Bid: 2.35
Ask: 2.41
Change: 0.23 (10.70%)
Spread: 0.06 (2.553%)
Open: 2.20
High: 2.45
Low: 2.20
Prev. Close: 2.15
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appoints Head of Investor Relations

29 Feb 2012 07:00

RNS Number : 3054Y
Immupharma PLC
29 February 2012
 



 

FOR IMMEDIATE RELEASE 29 FEBRUARY 2012

 

 

ImmuPharma plc

 

Appoints Head of Investor Relations

 

 

ImmuPharma plc (AIM: IMM), the specialist drug development company, is pleased to announce that it has appointed Lisa Baderoon as Head of Investor Relations.

 

Lisa Baderoon has spent over 20 years working within the City, the majority of that time as a Partner of Buchanan, one of the leading City financial public relations agencies, where she helped establish its successful healthcare franchise.

 

Commenting on her appointment Lisa Baderoon said:"At Buchanan I advised ImmuPharma for over six years so I am extremely excited that I now have the opportunity of working even more closely with the management team on its IR strategy at one of the most exciting and pivotal stages in its development."

 

Dimitri Dimitriou, Chief Executive Officer of ImmuPharma, added:"Lisa brings a wealth of experience to ImmuPharma having advised not only us but many other companies within the healthcare sector. We are therefore delighted that she is now going to be part of our team."

 

 

- Ends -

 

 

For further information please contact:

 

 

ImmuPharma plc

 

Dimitri Dimitriou, Chief Executive Officer Tel No: + 44 (0) 20 7152 4080

 

Lisa Baderoon, Head of Investor Relations Tel No: + 44 (0) 7721 413496

 

 

Buchanan  Tel No: + 44 (0) 20 7466 5000

 

Mark Court, Jessica Fontaine

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEASAPASSAEFF
Date   Source Headline
3rd May 20247:00 amRNSHolding(s) in Company
24th Apr 20247:12 amRNSIMMUPHARMA AT BIO-EQUITY 2024 12-14 May
19th Apr 20247:00 amRNSGrant of Share Options
2nd Apr 20247:03 amRNSNew intellectual property strategy initiated
25th Mar 20247:25 amRNSIncanthera provides Comm'l Update/Revenue F'casts
19th Mar 20247:00 amRNSGrant of Share Options
14th Mar 20247:00 amRNSIMMUPHARMA AT BIO-EUROPE SPRING 2024
6th Mar 20247:00 amRNSFinancial, Business and Portfolio Develop't Update
28th Dec 20231:35 pmRNSHolding(s) in Company
19th Dec 20232:50 pmRNSHolding(s) in Company
19th Dec 20237:00 amRNSSimbec-Orion appointed as CRO
18th Dec 20237:15 amRNSIncanthera - Comm'l Skincare Deal/£1M Fundraise
13th Sep 20233:47 pmRNSHolding(s) in Company
7th Sep 20237:00 amRNSResult of Retail Offer and Director Shareholding
31st Aug 20237:02 amRNSWRAP Retail Offer for up to £0.5m
31st Aug 20237:01 amRNSSubscription to raise £1.35m; Sharing Agr, RPT
31st Aug 20237:00 amRNSInterim results
21st Aug 20237:00 amRNSExtension of warrants in Incanthera plc
11th Aug 202312:04 pmRNSDirectorate Change
30th Jun 20231:12 pmRNSResult of AGM
19th Jun 20237:00 amRNSLupuzor Update
6th Jun 20237:00 amRNSIMM RNS Posting of RA and Notice of AGM 30 June 23
18th May 20237:00 amRNSPositive Pre-IND meeting with FDA
11th May 20237:00 amRNSFinal Results
10th May 20231:56 pmRNSHolding(s) in Company
19th Apr 20237:00 amRNSLupozor Update - FDA confirms Type-C meeting date
12th Apr 20237:00 amRNSCIDP P140 Clinical Program Update
27th Mar 20237:00 amRNSLupuzor™ Update
9th Mar 20234:35 pmRNSPrice Monitoring Extension
6th Mar 20237:00 amRNSCollaboration with Orano on ImmuPharma Peptide
6th Feb 20237:00 amRNSLupuzor™ Update
27th Jan 20234:25 pmRNSTR-1: Notification of major holdings
4th Jan 20235:26 pmRNSTR-1: Notification of major holdings
4th Jan 20234:40 pmRNSSecond Price Monitoring Extn
4th Jan 20234:35 pmRNSPrice Monitoring Extension
3rd Jan 20234:58 pmRNSTR-1: Notification of major holdings
22nd Dec 20227:55 amRNSGrant of Options
22nd Dec 20227:00 amRNSEnd of Year Update
22nd Nov 20223:15 pmRNSHolding(s) in Company
14th Nov 20224:40 pmRNSSecond Price Monitoring Extn
14th Nov 20224:35 pmRNSPrice Monitoring Extension
11th Nov 20227:31 amRNSLupuzor Update
11th Oct 20224:40 pmRNSSecond Price Monitoring Extn
11th Oct 20224:35 pmRNSPrice Monitoring Extension
7th Oct 20224:44 pmRNSCompany Secretary Change
6th Oct 20225:17 pmRNSHolding(s) in Company
30th Sep 20227:30 amRNSLupuzor Update
30th Sep 20227:00 amRNSInterim Results or the 6mths Ended 30 June 2022
29th Sep 20224:40 pmRNSSecond Price Monitoring Extn
29th Sep 20224:37 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.